Table 3 Demographics of the study cohort and those with a medical or pharmacologic contraindication to mefloquine use, U.S. military personnel deployed to Afghanistan, 2007.
| Â | Â | Contraindication(s) to mefloquine | ||
|---|---|---|---|---|
| Â | Study cohort | Medical | Pharmacologic | Either or Both |
| Â | Number (%) | Number (%) | Number (%) | Number (%) |
Total | 11725 (100) | 558 (100) | 837 (100) | 1127 (100) |
Gender | Â | Â | Â | Â |
   Male | 10614 (90.5) | 463 (83.0) | 670 (80.0) | 916 (81.3) |
   Female | 1111 (9.5) | 95 (17.0) | 167 (20.0) | 211 (18.7) |
Race | Â | Â | Â | Â |
   White | 8552 (72.9) | 428 (76.7) | 626 (74.8) | 846 (75.1) |
   Black | 1967 (16.8) | 84 (15.1) | 118 (14.1) | 171 (15.2) |
   Other | 1206 (10.3) | 46 (8.2) | 93 (11.1) | 110 (9.8) |
Prior deployments | Â | Â | Â | Â |
   0 | 7119 (60.7) | 315 (56.5) | 494 (59.0) | 660 (58.6) |
   1 | 3442 (29.4) | 175 (31.4) | 256 (30.6) | 347 (30.8) |
   2+ | 1164 (9.9) | 68 (12.2) | 87 (10.4) | 120 (10.6) |
Military specialty | Â | Â | Â | Â |
   Combat | 2818 (24.0) | 112 (20.1) | 153 (18.3) | 214 (19.0) |
   Non-combat | 8907 (76.0) | 446 (79.9) | 684 (81.7) | 913 (81.0) |
Age | Â | Â | Â | Â |
   18–19 | 521 (4.4) | 27 (4.8) | 18 (2.2) | 38 (3.4) |
   20–29 | 7701 (65.7) | 356 (63.8) | 508 (60.7) | 702 (62.3) |
   30–39 | 2774 (23.7) | 138 (24.7) | 240 (28.7) | 301 (26.7) |
   40–49 | 688 (5.9) | 37 (6.6) | 66 (7.9) | 81 (7.2) |
   50+ | 41 (0.3) | 0 (0.0) | 5 (0.6) | 5 (0.4) |